Please assess the completion status of the following clinical trial:

Trial Title: Abatacept Post-marketing Clinical Study in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MTX inadequate responder~* Biologic Naïve~* Functional class I, II or III~* ≥6 swollen and ≥6 tender joints~* C-reactive protein (CRP) ≥2.0mg/dl or erythrocyte sedimentation rate (ESR) ≥28 mm/hr~* Anti-cyclic citrullinated peptide (CCP) antibody positive~* Have erosion~Exclusion Criteria:~* Any other rheumatic disease~* Active angiitis on main organs excluding rheumatoid nodule

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Abatacept + Methotrexate (MTX) (Type: EXPERIMENTAL): Abatacept 10 mg/kg solution intravenous (IV) infusion, once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months
- Group 2: Placebo matching with Abatacept + Methotrexate (Type: PLACEBO_COMPARATOR): Placebo matching with Abatacept 0 mg/kg solution, intravenous (IV) infusion once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).